News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phagenesis Ltd Wins CE Mark for Phagenyx ™ to Treat Dysphagia



10/16/2012 6:43:47 AM

Manchester, UK - 16th October 2012 - Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that its treatment system Phagenyx™, the world's first treatment for acute dysphagia following stroke, has been awarded a CE Mark.

Dysphagia, the inability to swallow safely, is a debilitating condition that affects about half of all stroke patients1. Dysphagia frequently leads to potentially life-threatening pneumonia and the surgical implantation of a PEG tube to allow a patient to be fed through the abdomen wall indefinitely.

The CE Mark paves the way for Phagenyx to be launched in Europe, where there are more than 1 million strokes per year2.

The Phagenyx™ treatment system delivers a calibrated electrical signal to the back of the throat (oropharynx) for 10 minutes a day for three consecutive days. This protocol has shown to lead to a clinicially and statistically significant improvement in swallowing function in a majority of dysphagia patients. Phagenyx is the result of almost 20 years of research and development, led by Professor Shaheen of the Salford Royal Hospital and the University of Manchester.

Daniel Green, CEO of Phagenesis, said: “The Phagenyx™ treatment system allows doctors, nurses and speech and language therapists to alleviate the suffering of hundreds of thousands of stroke patients across the world. The CE marking will allow the system to be rolled out across Europe and other territories.”

About Phagenesis

Phagenesis has developed the first clinically proven treatment for dysphagia, a debilitating and often lethal condition in which the patient’s ability to swallow is damaged. Dysphagia can lead to the inhalation of solids or liquids followed by pneumonia. Sufferers may face being fed through a tube indefinitely, reduced life expectancy, and many are treated for depression. Phagenesis announced a £2 million Series A financing in 2010 and a €7m Series B financing in 2011. For more information, please visit our website at www.phagenesis.com.

For more information, please contact:

Daniel Green

CEO

Phagenesis

daniel.green@phagenesis.com

+44 (0)161 820 4525

+ 44(0)161 820 4524

+44 (0)7968 183512


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES